Myeloma: Pathology, Diagnosis, and Treatment

Edited by

Stephen A. Schey
Professor of Plasma Cell Dyscrasias, King's College London;
Consultant Haematologist,
King's College Hospital NHS Foundation Trust, London, UK

Kwee L. Yong
Professor of Haematology, University College London;
Consultant Haematologist,
University College London Hospitals, London, UK

Robert Marcus
Consultant Haematologist,
King's College Hospital NHS Foundation Trust, London, UK

Kenneth C. Anderson
Kraft Family Professor of Medicine, Harvard Medical School;
Medical Director, Kraft Family Blood Donor Center,
Dana-Faber Cancer Institute, Boston, MA, USA
# Contents

## List of contributors

vi

## Section 1 – Overview of myeloma

1. **Epidemiology of myeloma**
   - Eve Roman and Alexandra G. Smith
   
2. **Diagnosis of myeloma and related plasma cell disorders**
   - Roger Owen
   
3. **Imaging of myeloma**
   - Nicola Mulholland and Ming Young Simon Wan

## Section 2 – Biological basis for targeted therapies in myeloma

4. **Cell cycle regulation and myeloma precursor cells**
   - John Quinn and Kwee L. Yong

5. **The genetic and epigenetic mechanisms underlying the behavior of myeloma**
   - Martin F. Kaiser, Kevin D. Boyd and Gareth J. Morgan

6. **The myeloma bone marrow environment and survival signaling**
   - Asim Khwaja, John Quinn and Kwee L. Yong

7. **Immune dysfunction in multiple myeloma**
   - Guy Pratt and Paul Moss

8. **Myeloma bone disease – pathogenesis of bone destruction and therapeutic strategies**
   - Andrew Chantry and Neil Rabin

9. **Principles of pathway directed therapy**
   - Yu-Tzu Tai and Kenneth C. Anderson

## Section 3 – Myeloma: clinical entities

10. **Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma**
    - Efstathios Kastritis and Meletios A. Dimopoulos

11. **Multiple myeloma: management of de novo disease to include HDT**
    - T. Guglielmelli, P. Sonneveld, A. Broyl and A. Palumbo

12. **Treatment of relapsed/refractory myeloma**
    - Matthew J. Streetly, Jacob Laubach, Paul Richardson and Stephen A. Schey

13. **Solitary bone and extra-medullary plasmacytoma**
    - Shirley D’Sa and Eve Gallop-Evans

14. **Amyloidosis**
    - Ashutosh D. Wechalekar, Simon W. Dubrey and Raymond L. Comenzo

15. **Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma**
    - Steven P. Treon and Giampaolo Merlini

16. **Castleman’s disease**
    - Karthik Ramasamy

17. **POEMS syndrome and paraproteinemic syndromes: management and follow-up**
    - Angela Dispenzieri and Suzanne R. Hayman

## Section 4 – Supportive therapies

18. **Treatment of emergent peripheral neuropathy in plasma cell disorders**
    - Charise Gleason, Melanie Watson and Sagar Lonial
## Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Management of renal failure in multiple myeloma</td>
<td>Aneel Paulus, Pooja Advani, Nabeel Aslam and Asher Alban Chanan-Khan</td>
</tr>
<tr>
<td>20</td>
<td>The management of infection in myeloma</td>
<td>Christopher P. Conlon</td>
</tr>
</tbody>
</table>

Index 288
Contributors

Pooja Advani
Department of Internal Medicine, State University of New York at Buffalo, Buffalo, NY, USA

Kenneth C. Anderson
Harvard Medical School, and Kraft Family Blood Donor Center, Dana-Faber Cancer Institute, Boston, MA, USA

Nabeel Aslam
Department of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA

Kevin D. Boyd
Haemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey, UK

A. Broyl
Department of Hematology, University Hospital Rotterdam, Rotterdam, Netherlands

Asher Alban Chanan-Khan
Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA

Andrew Chantry
Department of Oncology, Medical School, The University of Sheffield, Sheffield, UK

Raymond L. Comenzo, MD
Blood Bank and Neely Cell Processing and Collection Center; Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center; and Tufts University School of Medicine, Boston, MA, USA

Christopher P. Conlon
Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK

Shirley D’Sa
Department of Haematology, University College London Hospital, London, UK

Meletios A. Dimopoulos
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Angela Dispenzieri
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA

Simon W. Dubrey
Department of Cardiology, Hillingdon and Mount Vernon Hospitals NHS Trust, Middlesex; Department of Cardiology, Royal Brompton and Harefield NHS Trust, London; and Imperial College School of Medicine, London, UK

Eve Gallop-Evans
Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK

Charise Gleason
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

T. Guglielmelli
Unit of Hematology, “S. Luigi Gonzaga” Hospital, Orbassano, Torino, Italy

Suzanne R. Hayman
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA

Martin F. Kaiser
Haemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey, UK
List of contributors

Efstathios Kastritis
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Asim Khwaja
Department of Haematology, University College London, and University College London Hospitals NHS Trust, London, UK

Jacob Laubach
Hematologic Malignancies Center, Dana-Faber Cancer Institute, Boston, MA, USA

Sagar Lonial
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

Robert Marcus
King’s College Hospital NHS Foundation Trust, London, UK

Giampaolo Merlini
Department of Biochemistry, University of Pavia, and Biotechnology Research Laboratories, University Hospital Policlinico San Matteo, Pavia, Italy

Gareth J. Morgan
Haemato-oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey, UK

Paul Moss
School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, UK

Nicola Mulholland
Department of Nuclear Medicine, King’s College Hospital, London, UK

Roger Owen
HMDS Laboratory, St James’ University Hospital, Leeds, UK

Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

Aneel Paulus
Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA

Guy Pratt
Department of Haematology, School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, UK

John Quinn
Department of Haematology, RCSI/Beaumont Hospital, Dublin, Ireland

Neil Rabin
Department of Haematology, University College London Hospitals NHS Trust, London, UK

Karthik Ramasamy
Department of Haematology, Oxford University Hospitals NHS Trust and Royal Berkshire NHS Foundation Trust, UK

Paul Richardson
Hematologic Malignancies Center, Dana-Faber Cancer Institute, Boston, MA, USA

Eve Roman
Department of Health Sciences and Hull York Medical School, University of York, York, UK

Stephen A. Schey
Department of Haematology, King’s College London, and King’s College Hospital NHS Foundation Trust, London, UK

Alexandra G. Smith
Department of Health Sciences and Hull York Medical School, University of York, York, UK

P. Sonneveld
Department of Hematology, University Hospital Rotterdam, Rotterdam, Netherlands

Matthew J. Streetly
Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Yu-Tzu Tai
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Steven P. Treon
Bing Center for Waldenstrom’s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
<table>
<thead>
<tr>
<th>List of contributors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ming Young Simon Wan</strong></td>
</tr>
<tr>
<td>Department of Radiology, King's College Hospital, London, UK</td>
</tr>
<tr>
<td><strong>Melanie Watson</strong></td>
</tr>
<tr>
<td>Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA</td>
</tr>
<tr>
<td><strong>Ashutosh D. Wechalekar</strong></td>
</tr>
<tr>
<td>National Amyloidosis Centre, University College London Medical School, London, UK</td>
</tr>
<tr>
<td><strong>Kwee L. Yong</strong></td>
</tr>
<tr>
<td>UCL Cancer Institute, University College London, London, UK</td>
</tr>
</tbody>
</table>